Resveratrol improves endothelial function in patients with kidney disease and diabetes, study shows
Highlights
- Randomized, double-blind, placebo-controlled, cross-over trial involving 21 older adults with stage 3 CKD and diabetes
- Supplementation consist of ResVida 99% pure, all-trans resveratrol supplementation (200 mg/day, twice daily) for 6 weeks (treatment and matching placebo provided by Endurance Products Company)
- Compared to placebo, resveratrol significantly improves endothelial function as measured by the change in brachial artery flow-mediated dilation
Summary
This randomized, double-blind, placebo-controlled, crossover trial was designed to investigate the effects of resveratrol supplementation on endothelial function in older adults with chronic kidney disease (CKD) and diabetes. The participants, who were between the ages of 45 and 80, were recruited from the Nephrology Clinics at the University of Iowa and the Iowa City Veterans Affairs Healthcare System.
Inclusion criteria included stage 3 CKD, diabetes, and controlled hypertension. Exclusion criteria included consuming more than two glasses of red wine per day, current use or use of resveratrol or vitamin C supplements within the last 12 months, life expectancy of less than one year, body mass index (BMI) greater than 40 kg/m2, and free of other confounding medical conditions or medication use.
Participants were assigned to either treatment or placebo for 6 weeks in random order with a 2-week washout period between interventions and instructed to take two 100-mg tablets of ResVida resveratrol twice day for 6 weeks (400 mg/day).
Study products (ResVida 99% pure trans-resveratrol and matching placebo) were donated by Endurance Products Company. The primary outcome measure was endothelial function as measured by the change in brachial artery flow-mediated dilation.
A total of 23 participants completed the study (82%; 23/28). Study withdrawals were unrelated to treatment (e.g., changes in health/medications, study burden, COVID pandemic). Of the 23 completers, 21 had complete data for analysis. Results indicate that, compared to placebo, resveratrol significantly increased flow-mediated dilation with a mean between-group comparison ratio of 1.43 (P<.001). Resveratrol supplement adherence was excellent (96%) and well tolerated.
No significant differences were reported in any other parameters measured (e.g., vascular smooth muscle function as measured by nitroglycerin-mediated dilation, blood pressure, eGFR, and HbA1c), suggesting the improvement in flow-mediated dilation was likely independent of changes in traditional cardiovascular risk factors outcomes.
These preliminary findings indicate that supplementation with ResVida resveratrol (200 mg, twice daily, for 6 weeks) may offer therapeutic value for improving endothelial function in older patients with stage 3 CKD and diabetes.
Related Products
- Resveratrol 100mg
Reference
Gimblet CJ, Kruse NT, Geasland K, et al. Effect of resveratrol on endothelial function in patients with CKD and diabetes: a randomized controlled trial. Clin J Am Soc Nephrol. Published online October 16, 2023. https://pubmed.ncbi.nlm.nih.gov/37843843/
